This year, magAssist showcased its innovative multi-scenario MCS achievements based on a unified control platform at several key sessions of the conference, including MoyoAssist.^®Extra VAD, NyokAssist^®Percutaneous short-term ventricular assist device (pVAD), along with the engineering logic behind it, clinical application experience, and thoughts on internationalization strategies. The technical consistency and cross-scenario scalability reflected in its platform-based product system have drawn significant attention from international peers.

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyProfessor Chen ShuPresentation on "The Latest Advances in China's Extracorporeal Ventricular Assist Devices" was delivered at the conference, with its latest data and practical usage experience providing new evidence from China to the field of international short-term circulatory support. As an extracorporeal ventricular assist device with full magnetic levitation approved by NMPA, MoyoAssist^®The technical design and clinical performance are derived from a deep understanding of clinical needs.

MoyoAssist^®AdoptFully Magnetically Levitated Blood PumpDesign, through flow field optimization,Effectively Reduces the Risk of Hemolysis and Thrombosis——Experimental data shows that its in vitro hemolytic performance is comparable to international counterparts. The system has good anti-vibration and continuous operational stability, making it suitable for use in the ICU, operating room, and during patient transfer. The main unit weighs 8kg, with a battery life of ≥2 hours, and it features an IPX4 waterproof rating to meet the demands of real clinical environments.

Data from a 40-case prospective multicenter clinical trial for MoyoAssist^®Provides solid support for its clinical value, and the research results show:

The real-world application after market launch further demonstrated MoyoAssist^®Cross-scenario flexibility: Its applications have covered various clinical scenarios requiring extracorporeal mechanical circulatory support, such as bridge-to-transplant and myocarditis recovery bridging. Data shows,A total of 74% of patients successfully weaned off the ventilator.`, and the majority of cases utilize a minimally invasive percutaneous implantation approach, which not only reduces surgical trauma but also helps patients recover more quickly. The dual validation from prospective trials and real-world data has further solidified the credibility of MoyoAssist.`^®In the global short-term VAD treatment system, it has gradually become a "Chinese solution" with important reference value.

Zhongshan Hospital, Fudan UniversityDr. Rui WangShared at the conference: "SAVE-PCI: NyokAssist^®A Comparative Study of Small-sized VAD and IABP in Elective High-risk PCI". This is one of the few pVAD RCT studies led by a Chinese team internationally, following...TCT Conference Late Breaking Heavyweight ReleaseAfterward, it once again sparked widespread discussion in the MCS academic community.

NyokAssist^®The core design lies in achieving an optimal balance between minimally invasive properties and blood flow support efficiency: adopting9Fr Small-Size Access + Foldable Impeller Structure, while reducing the risk of vascular-related complications, it is able to provide stable blood flow support that meets the demands of PCI procedures with extremely low hemolysis. The external motor design simplifies the implantation and removal processes, enhancing the convenience of clinical operations.

This 1:1 randomized controlled trial, which enrolled 236 patients undergoing elective high-risk PCI, showed that, compared with IABP:

This study, with its rigorous trial design and sufficient sample size, provides a new evidence-based option for circulatory support in high-risk PCI patients globally.

At this conference, magAssist not only showcased the clinical outcomes of its products but also systematically broke down its underlying R&D system through multiple academic presentations. It demonstrated how a platform-based product architecture supports multi-scenario expansion, conveying the important concepts of systematic R&D and cross-disciplinary collaboration.

Founder of magAssistDr. Xu BotingIn the keynote speech on "Industry Progress," insights were shared on the technological advancements and industrial practices in the MCS field: from the iterative evolution of the core model of magnetic levitation blood pumps, to the support logic of a platform-based control system for multi-module products, to clinical pathway planning and registration strategies covering multiple countries. These contents demonstrate not just the breakthrough of a single product, but a sustainably iterative technological system.

Vice President of magAssistMr. Yan YifanFrom the perspective of the intersection of engineering and clinical practice, a key parameter evaluation model for MCS devices was shared, including dimensions such as blood flow targets, operational complexity, human factors engineering, and safety, providing a referenceable design framework for global peers.

This trip to Vienna is not only an important opportunity for magAssist to showcase its latest technological achievements and clinical evidence globally, but also a crucial step in deepening interactions and collaborations with the international MCS community. As the dual-center strategy in China and the US gradually unfolds, magAssist will continue to enhance its global engagement across multiple dimensions.

Based on a platform-based technology system, magAssist will continue to promote MoyoAssist.^®、NyokAssist^®And in the future, modular products will enter more countries, committed to providing more reliable and accessible circulatory support solutions for critically ill cardiovascular patients worldwide.